ReviewBiomaterials2019
In vitro and ex vivo systems at the forefront of infection modeling and drug discovery.
Review in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species.Emerging microbes & infections · 2026Article
- Human airway organoids for bacterial-host interaction studies: methods, insights and translational promise.Thorax · 2026Review
- Investigation of the anti-microbial and anti-inflammatory properties of Weizmannia coagulans MBBCM9™ and formulation of a probiotic oral health product.World journal of microbiology & biotechnology · 2026Article
- Universal-BacMicrobiologyOpen · 2026Article
- Can Complex 3D Models Effectively Replace 2D and Animal Models to Investigate the Microbe-Tumor-Immune Axis in Pancreatic Cancer Studies?Nutrients · 2026Review
- Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance.International journal of molecular sciences · 2026Review
- Comprehension of the age-dependent gut and brain interaction of honey bee workers by integration of multi omics approaches.Journal of advanced research · 2026Article
- Mitigating sepsis-induced vascular endothelial dysfunction through Niban phosphorylation.Vascular medicine (London, England) · 2026Article
- Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems.The Journal of antimicrobial chemotherapy · 2026Review
- Parkinson's-Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Infectious Diarrhea in Early Childhood across the Global South: Etiologic Diversity and Pathogenic Mechanisms.ACS infectious diseases · 2026Review
- Nanomedicine Strategies Against Biofilm-Associated Infections: Advances, Challenges, and Translational Barriers.MicrobiologyOpen · 2026Review
- Endothelial dysfunction in aging associated with reduced Niban phosphorylation.Molecular biology reports · 2026Article
- Emerging therapeutic drug targets in amino acid and protein biosynthesis pathways against ESKAPE and non-ESKAPE pathogens: a comprehensive review.Archives of microbiology · 2026Review
- Hypertonic thermal solutions as a putative strategy for respiratory biofilm disruption.Open medicine (Warsaw, Poland) · 2026Article
- Lipopolysaccharide-induced alterations in barrier integrity and inflammatory signaling in porcine small intestinal organoids.PloS one · 2026Article
- Test parameter selection affects the perceived antibacterial efficacy of a contact-killing coating developed to prevent prosthetic joint infection.Frontiers in bioengineering and biotechnology · 2026Article
- Feasibility of a rat femoral-defect model for immediate perioperative and delayed post-implantation implant-associated bone infections.Journal of bone and joint infection · 2026Article
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Er:YAG Laser Energy Optimization for Reducing Single-Species Microbial Growth on Agar Surfaces In Vitro.Pathogens (Basel, Switzerland) · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial infections and antibiotic resistant bacteria have become a growing problem over the past decade. As a result, the Centers for Disease Control predict more deaths resulting from microorganisms than all cancers combined by 2050. Currently, many traditional models used to study bacterial infections fail to precisely replicate the in vivo bacterial environment. These models often fail to incorporate fluid flow, bio-mechanical cues, intercellular interactions, host-bacteria interactions, and even the simple inclusion of relevant physiological proteins in culture media. As a result of these inadequate models, there is often a poor correlation between in vitro and in vivo assays, limiting therapeutic potential. Thus, the urgency to establish in vitro and ex vivo systems to investigate the mechanisms underlying bacterial infections and to discover new-age therapeutics against bacterial infections is dire. In this review, we present an update of current in vitro and ex vivo models that are comprehensively changing the landscape of traditional microbiology assays. Further, we provide a comparative analysis of previous research on various established organ-disease models. Lastly, we provide insight on future techniques that may more accurately test new formulations to meet the growing demand of antibiotic resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.